Dual CFTR Modulator Therapy Efficacy in the Real World: Lessons for the Future

Overview

Journal ERJ Open Res

Specialty Pulmonary Medicine

Date 2022 Nov 16

PMID 36382239

Authors

Anna-Maria Dittrich

Sandra Y Chuang

Affiliations

Soon will be listed here.

Abstract

https://bit.ly/3dJt6no.

Citing Articles

Longitudinal changes in habitual physical activity in adult people with cystic fibrosis in the presence or absence of treatment with elexacaftor/tezacaftor/ivacaftor.

Gruber W, Stehling F, Blosch C, Dillenhoefer S, Olivier M, Brinkmann F Front Sports Act Living. 2024; 6:1284878.

PMID: 38463712 PMC: 10921570. DOI: 10.3389/fspor.2024.1284878.

CFTR Function Restoration upon Elexacaftor/Tezacaftor/Ivacaftor Treatment in Patient-Derived Intestinal Organoids with Rare Genotypes.

Lefferts J, Bierlaagh M, Kroes S, Nieuwenhuijze N, Sonneveld van Kooten H, Niemoller P Int J Mol Sci. 2023; 24(19).

PMID: 37833986 PMC: 10572896. DOI: 10.3390/ijms241914539.

Spirometric and anthropometric improvements in response to elexacaftor/tezacaftor/ivacaftor depending on age and lung disease severity.

Schutz K, Pallenberg S, Kontsendorn J, DeLuca D, Sukdolak C, Minso R Front Pharmacol. 2023; 14:1171544.

PMID: 37469865 PMC: 10352657. DOI: 10.3389/fphar.2023.1171544.

References

Aalbers B, Hofland R, Bronsveld I, de Winter-de Groot K, Arets H, de Kiviet A . Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males. J Cyst Fibros. 2020; 20(1):e7-e11. DOI: 10.1016/j.jcf.2020.05.004. View

Rosenfeld M, Wainwright C, Higgins M, Wang L, McKee C, Campbell D . Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med. 2018; 6(7):545-553. PMC: 6626762. DOI: 10.1016/S2213-2600(18)30202-9. View

Bessonova L, Volkova N, Higgins M, Bengtsson L, Tian S, Simard C . Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor. Thorax. 2018; 73(8):731-740. PMC: 6204955. DOI: 10.1136/thoraxjnl-2017-210394. View

Rowe S, Daines C, Ringshausen F, Kerem E, Wilson J, Tullis E . Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med. 2017; 377(21):2024-2035. PMC: 6472479. DOI: 10.1056/NEJMoa1709847. View

Muilwijk D, Zomer-van Ommen D, Gulmans V, Eijkemans M, van der Ent C . Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis. ERJ Open Res. 2022; 8(4). PMC: 9661249. DOI: 10.1183/23120541.00204-2022. View

Nichols D, Paynter A, Heltshe S, Donaldson S, Frederick C, Freedman S . Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2021; 205(5):529-539. PMC: 8906485. DOI: 10.1164/rccm.202108-1986OC. View

Davies J, Wainwright C, Sawicki G, Higgins M, Campbell D, Harris C . Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2020; 203(5):585-593. PMC: 7924576. DOI: 10.1164/rccm.202008-3177OC. View

Konstan M, McKone E, Moss R, Marigowda G, Tian S, Waltz D . Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2016; 5(2):107-118. DOI: 10.1016/S2213-2600(16)30427-1. View

Muilwijk D, Bierlaagh M, van Mourik P, Kraaijkamp J, van der Meer R, van den Bor R . Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators. J Pers Med. 2021; 11(12). PMC: 8707616. DOI: 10.3390/jpm11121376. View

10.

Davies J, Cunningham S, Harris W, Lapey A, Regelmann W, Sawicki G . Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med. 2016; 4(2):107-15. PMC: 6734927. DOI: 10.1016/S2213-2600(15)00545-7. View

11.

Taylor-Cousar J, Munck A, McKone E, van der Ent C, Moeller A, Simard C . Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N Engl J Med. 2017; 377(21):2013-2023. DOI: 10.1056/NEJMoa1709846. View

12.

Rayment J, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M . A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for . Am J Respir Crit Care Med. 2022; 206(10):1239-1247. PMC: 9746849. DOI: 10.1164/rccm.202204-0734OC. View

13.

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

14.

Guimbellot J, Solomon G, Baines A, Heltshe S, VanDalfsen J, Joseloff E . Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros. 2018; 18(1):102-109. PMC: 6196121. DOI: 10.1016/j.jcf.2018.04.004. View

15.

McNamara J, McColley S, Marigowda G, Liu F, Tian S, Owen C . Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir Med. 2019; 7(4):325-335. DOI: 10.1016/S2213-2600(18)30460-0. View

16.

Secunda K, Guimbellot J, Jovanovic B, Heltshe S, Sagel S, Rowe S . Females with Cystic Fibrosis Demonstrate a Differential Response Profile to Ivacaftor Compared with Males. Am J Respir Crit Care Med. 2019; 201(8):996-998. PMC: 7159427. DOI: 10.1164/rccm.201909-1845LE. View

17.

Bell S, Mall M, Gutierrez H, Macek M, Madge S, Davies J . The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2019; 8(1):65-124. PMC: 8862661. DOI: 10.1016/S2213-2600(19)30337-6. View

18.

Kirwan L, Fletcher G, Harrington M, Jeleniewska P, Zhou S, Casserly B . Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland. Ann Am Thorac Soc. 2018; 16(2):209-216. DOI: 10.1513/AnnalsATS.201802-149OC. View

19.

Volkova N, Moy K, Evans J, Campbell D, Tian S, Simard C . Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries. J Cyst Fibros. 2019; 19(1):68-79. DOI: 10.1016/j.jcf.2019.05.015. View

20.

Barry P, Mall M, Alvarez A, Colombo C, de Winter-de Groot K, Fajac I . Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes. N Engl J Med. 2021; 385(9):815-825. PMC: 8982185. DOI: 10.1056/NEJMoa2100665. View